Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Celldex Therapeutics Inc

CLDX
Current price
31.43 USD -0.44 USD (-1.38%)
Last closed 31.6 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 751 148 160 USD
Yield for 12 month -15.40 %
Week
Month
Year
CLDX
21.11.2021 - 28.11.2021

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey. Address: Perryville III Building, Hampton, NJ, United States, 08827

Analytics

WallStreet Target Price

55.71 USD

P/E ratio

Dividend Yield

2.16 %

Current Year

+2 357 000 USD

Last Year

+4 651 000 USD

Current Quarter

+1 517 000 USD

Last Quarter

+268 000 USD

Current Year

+2 357 000 USD

Last Year

+4 651 000 USD

Current Quarter

+1 517 000 USD

Last Quarter

+268 000 USD

Key Figures CLDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -131 878 000 USD
Operating Margin TTM -2718.46 %
PE Ratio
Return On Assets TTM -25.94 %
PEG Ratio
Return On Equity TTM -42.09 %
Wall Street Target Price 55.71 USD
Revenue TTM 4 365 000 USD
Book Value 5.22 USD
Revenue Per Share TTM 0.092 USD
Dividend Share
Quarterly Revenue Growth YOY 272.7 %
Dividend Yield 2.16 %
Gross Profit TTM -79 901 000 USD
Earnings Share -2.65 USD
Diluted Eps TTM -2.65 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CLDX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CLDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 2.16 %
Last Split Factor 1:15
Payout Ratio
Last Split Date 11.02.2019
Dividend Date 11.02.2019

Stock Valuation CLDX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 348.5408
Price Sales TTM 401.1794
Enterprise Value EBITDA -11.5363
Price Book MRQ 7.1089

Financials CLDX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CLDX

For 52 weeks

22.11 USD 48.4 USD
50 Day MA 26.67 USD
Shares Short Prior Month 5 614 695
200 Day MA 32.58 USD
Short Ratio 7.38
Shares Short 7 882 546
Short Percent 17.02 %